Dupilumab boosts esophageal distensibility, diameter for EoE

CHICAGO — Dupilumab significantly improved esophageal distensibility and diameter in eosinophilic esophagitis at 24 weeks, alongside marked gains in endoscopic and histologic disease outcomes, data presented at Digestive Disease Week showed.
“Esophageal strictures and narrowing, also called fibrostenosis, are commonly seen in EoE, and traditionally are treated with esophageal dilation,” Evan S. Dellon, MD, MPH, director of the Center for Esophageal Diseases and Swallowing at University of North Carolina School of Medicine at Chapel Hill, told Healio. “However, some clinical data suggested that